Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up News

Executive Summary

Noteworthy news from medtech start-ups. This month we profile Magellan Spine Technologies, which aims to improve disc annular repair and r4 vascular, which is developing biomimetic-coated catheters.

You may also be interested in...



Anulex Technologies Inc.

One of the few surgical procedures that does not routinely involve closing tissue is a lumbar discectomy to repair a disc herniation, because up until recently there has been no easy and effective technique. The standard of care is to let the surgical opening attempt to heal on its own. However this neglect results in roughly 15% of cases requiring reoperation due to reherniation. Anulex Technologies Inc.’s Xclose tissue repair system provides surgeons with the opportunity to approximate and close the tissue of the anulus fibrosus immediately following a discectomy.

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

Director of the FDA’s center for drugs slams firm for failing to reach out before suspending operations in the wake of an inspection that raised serious data integrity concerns. Instead, firms should be alerting the agency as soon as they realize there could be shortages.

‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars

Marking a decade since Celltrion’s Remsima version of infliximab became the first monoclonal antibody biosimilar approved in Europe, Kevin Byoung Seo Choi, senior vice president and head of the marketing division at Celltrion Healthcare, talks to Generics Bulletin about the firm’s progress so far and the “room for improvement” that the company perceives in areas such as regulation, market access and pricing, supply chain and procurement – as well as what the future holds for the Korean biosimilars giant.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel